Estimation of the overall effect of a vaccine program is essential, but the effect is typically estimated for a whole program. We estimated the overall effect of the Quebec rotavirus vaccine program, launched in November 2011, and the effect for each 10% increase in rotavirus vaccine coverage on pediatric hospitalizations for all-cause acute gastroenteritis. We implemented negative binomial regressions adjusted for seasonality, long-term trends, and infection dynamics, to estimate the effect of the vaccine program as: 1) a dichotomous variable, representing program presence/absence, and linear term to account for changes in trend in the period after the program began; and 2) a continuous variable, representing rotavirus vaccine coverage. Using exposure 1, the vaccine program was associated with a 51.2% (95% confidence interval (CI): 28.5, 66.7) relative decline in adjusted weekly hospitalization rates for all-cause acute gastroenteritis as of December 28, 2014. Using exposure 2, a 10% increase in rotavirus ≥1-dose coverage was associated with a 7.1% (95% CI: 3.5, 10.5) relative decline in adjusted weekly rates, with maximum coverage of 87.0% associated with a 47.2% (95% CI: 26.9, 61.9) relative decline. Estimation of the overall effect attributable to a change in vaccine coverage might be a useful addition to standard measurement of the overall effect. Not all vaccine programs are created equal. With the adoption of a vaccine, policy makers must make numerous allocation decisions, which can influence the overall effect, or impact, of a vaccine program on disease burden. For example, decisions regarding the choice of vaccine(s), the population(s) targeted, and the schedule and dosage can influence the effect of a vaccine program on a disease outcome from a population perspective (1).
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Estimation of the overall effect of a vaccine program is essential, but the effect is typically estimated for a whole program. We estimated the overall effect of the Quebec rotavirus vaccine program, launched in November 2011, and the effect for each 10% increase in rotavirus vaccine coverage on pediatric hospitalizations for all-cause acute gastroenteritis. We implemented negative binomial regressions adjusted for seasonality, long-term trends, and infection dynamics, to estimate the effect of the vaccine program as: 1) a dichotomous variable, representing program presence/absence, and linear term to account for changes in trend in the period after the program began; and 2) a continuous variable, representing rotavirus vaccine coverage. Using exposure 1, the vaccine program was associated with a 51.2% (95% confidence interval (CI): 28.5, 66.7) relative decline in adjusted weekly hospitalization rates for all-cause acute gastroenteritis as of December 28, 2014 . Using exposure 2, a 10% increase in rotavirus ≥1-dose coverage was associated with a 7.1% (95% CI: 3.5, 10.5) relative decline in adjusted weekly rates, with maximum coverage of 87.0% associated with a 47.2% (95% CI: 26.9, 61.9) relative decline. Estimation of the overall effect attributable to a change in vaccine coverage might be a useful addition to standard measurement of the overall effect. Not all vaccine programs are created equal. With the adoption of a vaccine, policy makers must make numerous allocation decisions, which can influence the overall effect, or impact, of a vaccine program on disease burden. For example, decisions regarding the choice of vaccine(s), the population(s) targeted, and the schedule and dosage can influence the effect of a vaccine program on a disease outcome from a population perspective (1) .
Prior to program implementation, mathematical models are useful for estimating potential effects of different program scenarios (2-4), but model estimates are often uncertain (3, 5, 6) . Evaluation of the overall effect using real-world data after implementation is therefore warranted (3) (4) (5) , and comparison of results across similar jurisdictions with different vaccine programs might provide insights into the consequences of program decisions on population health outcomes.
Yet, estimates of the overall effect from jurisdictions with differing levels of vaccine coverage are not easily compared.
The comparison is not straightforward because the overall effect represents the average of effects in vaccinated and unvaccinated individuals, weighted by the proportion of each group in the population (i.e., as determined by vaccine coverage) (4, (7) (8) (9) . One strategy for making measures of overall effect comparable is to characterize the relative reduction in a disease outcome that is attributable to a per-unit change in vaccine coverage. Doing so separates the overall effect of a program from the level of vaccine coverage achieved in the setting of the program and should make estimates of overall effect easier to compare across jurisdictions.
We have provided a real-world example of this strategy, estimating, as a function of vaccine coverage, the overall effect of a rotavirus vaccine program on pediatric hospitalizations for all-cause acute gastroenteritis (AGE) in Quebec, Canada. Before the vaccine was available, rotavirus produced annual epidemics with peak disease through the winter and spring in Quebec (10, 11) , causing approximately 72% of AGE hospitalizations among children less than 5 years of age during the 6-month epidemic period (11) . We estimated the overall effect of a vaccination program as a rate ratio attributable to a 10% change in rotavirus vaccine coverage. We also characterized the overall effect of the whole program, in accordance with standard practice, and discuss the utility of our nonstandard approach.
METHODS
To estimate the overall effect of the Quebec rotavirus vaccine program, we conducted a time-series analysis of weekly all-cause AGE hospitalizations between June 1, 1998, and December 28, 2014, among a random sample of children aged 8-35 months, residing in greater Montreal, Quebec.
Study setting
The Province of Quebec implemented a publicly funded rotavirus vaccine program in November 2011. Under the program, monovalent rotavirus vaccine (Rotarix; GlaxoSmithKline, Brentford, United Kingdom) was available at no cost to Quebec residents, with routine vaccination recommended at 2 and 4 months of age, and series initiation and completion by 20 weeks and 8 months of age, respectively (12) . Prior to the program, pentavalent (RotaTeq; Merck & Co., Inc., Kenilworth, New Jersey) and monovalent rotavirus vaccines were licensed in Canada in August 2006 (13) and October 2007 (14) and recommended for use by the National Advisory Committee on Immunization in January 2008 (15) and July 2010 (16), respectively; however recipients were required to pay for vaccination.
Greater Montreal is the largest metropolitan area in Quebec and the second largest in Canada, with a population of approximately 4 million residents (17) . All Quebec residents are covered by provincial health insurance, except for some temporary residents (18) .
Study population
We included greater Montreal residents aged 8-35 months who were members of the Population Health Record (PopHR) cohort in our analyses. As described elsewhere (19) , the PopHR cohort was created for research on health indicators, and represents an open, population-based, deidentified random sample of approximately 25% of greater Montreal residents with provincial health insurance. Health-care utilization data are tracked longitudinally for each cohort member from entry until death, emigration, or the cohort end date. Each year, cohort losses are replaced with a random sample of births and immigrants to maintain the population sampling fraction. The initial PopHR cohort was selected in 1998, with annual updates through 2014 at the time of our analyses.
Data sources
The PopHR cohort was created via linkages of provincial health insurance administrative databases maintained by the government organization: Régie de l'assurance maladie du Québec. Year and month for each cohort member's dates of birth, cohort entry, and cohort exit are provided, and member health-care utilization data is tracked via an anonymized, unique identifier.
Hospitalization data for each cohort member are obtained from a software system that captures administrative, clinical, and demographic information on hospital discharges (Maintenance et exploitation des données pour l'étude de la clientèle hospitalière (20) ), used by all Quebec hospitals. In this system, administrative codes are recorded for each hospital stay using the International Classification of Diseases (ICD), Ninth Revision, adapted for Quebec (ICD-9-QC), until 2006, and International Classification of Diseases, Tenth Revision, adapted for Canada (ICD-10-CA), afterward.
Exposure ascertainment
In separate analyses, we characterized the Quebec rotavirus vaccine program as either: 1) the presence or absence of the program; or 2) rotavirus vaccine coverage in the population.
Vaccine program. We divided the study period into periods before and after implementing the program, with the period before the program defined as weeks before November 14, 2011 , and the period after the program began as weeks including or after this date. We designated November 14, 2011, as the effective program start date in consideration of the program's implementation date and a lag of 2 weeks to account for the biological delay in the immune response to vaccination, a duration typically used in rotavirus direct vaccine-effectiveness studies (21) (22) (23) (24) .
Vaccine coverage. We estimated weekly ≥1-and ≥2-dose rotavirus vaccine coverage among Montreal residents aged 8-35 months using coverage data from control participants enrolled in an external test-negative case-control study of rotavirus vaccine effectiveness in Quebec (23). For reasons described previously (25), we assumed that rotavirus vaccine coverage among these participants was a reasonable proxy to estimate population rotavirus vaccine coverage, given that their vaccination status was representative of the case source population and their inclusion was unlikely to be associated with vaccine uptake. We used these coverage data because an immunization registry did not exist in Quebec before June 2014 (26) , and provincial coverage survey estimates were not available as a time series (27) . Coverage estimates derived using this method were previously validated via comparison with provincial coverage surveys, and simulations suggest minimal bias when highly accurate diagnostic tests are used to ascertain controls (25) .
In our main analyses, we used coverage data from eligible controls recruited at hospitals between February 2011 and December 2014 in Montreal and Sherbrooke, Quebec, because coverage did not vary by geographic location (25) . Only controls aged 8 months or older at the time of participation in the external study were eligible for inclusion in our coverage estimates. This age cutoff was chosen because a control's rotavirus vaccine history was assessed as of their participation date and was not expected to change after 8 months of age (28) . Using these eligibility criteria, we formed a retrospective cohort to assess weekly rotavirus vaccine coverage, with controls entering and exiting the cohort at 8 and 36 months of age, respectively. We assessed ≥1-and ≥2-dose rotavirus coverage each week to form a weekly time series, because we expected population vaccine coverage to increase rapidly following program implementation. Due to concerns that the age distribution of cohort members might differ from the PopHR cohort over time, weekly coverage estimates were age-standardized via direct standardization using the weekly distribution of children aged ≥8 and <12 months, 1 year, and 2 years of age in the PopHR cohort, via the R "epitools" package (R Foundation for Statistical Computing, Vienna, Austria) (29) . Using these methods, the earliest date that we could derive age-standardized coverage estimates was April 11, 2011 , or approximately 29 weeks before the implementation of the Quebec rotavirus vaccine program. Prior to that date, we assumed rotavirus vaccine coverage was 0%, but we modified this assumption in sensitivity analyses.
Outcome ascertainment
We examined weekly counts of AGE hospitalizations as our outcome. We aggregated outcomes by week because AGE hospitalizations occurred infrequently in our population, so daily counts included many zeros, and aggregation to monthly rates might have inadvertently obscured rotavirus epidemic patterns. We used AGE in consideration of potential changes in laboratory testing practices for rotavirus and/or ICD coding directives for AGE over time (30) . To identify relevant hospitalizations, we examined the primary diagnosis ICD code recorded for each hospital stay, and we counted hospitalizations with a matching primary code for AGE, as previously defined by Quebec researchers Bernard et al. (31) .
Statistical analyses
We used negative-binomial generalized linear models with a log-link function to estimate the overall effect of the Quebec vaccine program on weekly counts of AGE hospitalizations among children 8-35 months of age. A continuous, linear term indicating the week number of the time series, subsequently referred to as week time, and a weekly offset term to account for the denominator of children aged 8-35 months in the PopHR cohort were included in all models. In separate models, we characterized the exposure as: 1) the presence or absence of the rotavirus vaccine program; or 2) continuous vaccine coverage in the population.
For exposure 1, we created a dichotomous variable to represent the rotavirus vaccination program, coded as 0 in weeks before the program and as 1 in weeks after the program began. Because we expected the program effect to change over time due to increasing coverage, we considered adjustment for a change in trend in the period after the program began (3, 32) in models adjusting for seasonality, long-term trends, and infection dynamics. This change was captured via inclusion of a product term between the binary program variable and a linear variable accounting for week or season number in the period after the program began. We coded the final study week or season as 0 in the latter term to facilitate derivation of the full program effect and 95% confidence intervals of the vaccine program achieved at study completion (i.e., December 28, 2014) (33) . Therefore, in models with a linear trend, the exponentiated model coefficient for our dichotomous variable represented the rate ratio comparing fitted weekly rates of AGE hospitalizations in the final week or season of the study period versus the mean rate in the period before the program. We also report the percent relative decrease in weekly rates estimated as (1 -rate ratio) × 100, to facilitate interpretability.
For exposure 2, we used weekly age-standardized proportions of either ≥1-or ≥2-dose rotavirus vaccine coverage multiplied by 100 (in separate models), with weeks before April 11, 2011, coded as 0. The exponentiated model coefficient for exposure 2 represented the rate ratio of weekly AGE hospitalizations corresponding to a 1% increase in vaccine coverage. To facilitate interpretability, we also report rate ratios and the percent relative decrease in our weekly outcome associated with a 10% increase in vaccine coverage and with an increase to the maximum coverage level observed during the study period. Because this representation assumes a log-linear relationship between our exposure and outcome, we examined the validity of this characterization in separate analyses (Web Appendix 1, available at https://academic.oup.com/aje).
We considered several different approaches to adjust for rotavirus seasonality, and we implemented a series of models with season included as either: 1) time strata; 2) a Fourier transformation of week time (t) using combinations of annual ( ) πt 2 52 and biennial ( )
sine and cosine terms; 3) a cubic B-spline transformation of calendar week time (i.e., using a January start date for week number; with the number of annual knots varying between 3 and 10); or 4) a combination of these approaches (34) . To account for possible shifts in rotavirus seasonality after the vaccination program, we also evaluated inclusion of separate Fourier terms for periods before and after the program began (35) . We considered adjustment for long-term trends by inclusion of a linear annual term for rotavirus season with June as a starting month, as used previously in Quebec (36) .
Due to the annual dynamic between the susceptible-infectedrecovered populations within a rotavirus season, we also considered adjustment for the "population recovered and immune to rotavirus," defined as the cumulative number of participants hospitalized for AGE per annual rotavirus season (37, 38) , with separate terms for before and after the program began. This approach assumes that: 1) hospitalizations for AGE are a surrogate for rotavirus hospitalizations, and 2) people who contract rotavirus within each season are immune for the remainder of the season after recovery. While these assumptions represent an oversimplification, they are expected to generally hold because rotavirus was the predominant cause of Canadian pediatric AGE in the period before the vaccination program (10, 11, 31, 36, (39) (40) (41) , and approximately one-half of our cohort was replaced each rotavirus season by an incoming birth cohort, which presumably represented children susceptible to rotavirus.
We selected the best-fitting model for each exposure by minimizing the Akaike information criterion (AIC), which includes a penalty to discourage overfitting (42, 43) , and we compared model fit among final models selected for each exposure by calculating AIC differences. We used Burnham and Anderson's (44) general criteria to denote AIC differences of 1-2, 4-7, and >10 as models with similar, moderately better, or conclusively better fit, respectively. In situations where the best candidate models had similar fit, we selected the most parsimonious model as the preferred model.
After selection of the best-fitting model for each exposure, we considered inclusion of one of the following autoregressive terms lagged by 1 week to address residual autocorrelation: 1) model residuals, 2) our outcome, 3) the logarithm of our outcome + 1, or 4) the logarithm of our outcome + 0.5. This approach has been suggested by several authors to reduce strong residual autocorrelation in infectious-disease time series induced by the contagious nature of the outcome (37, 45, 46) . We chose a lag of 1 week in consideration of the short incubation period of rotavirus (47) . For terms 3 and 4, the addition of 1 or 0.5 to outcome counts was implemented to prevent taking the logarithm of zero. We selected the best-fitting autoregressive term in consideration of its effect on residual autocorrelation, examined via autocorrelation and partial autocorrelation functions (48) , and AIC differences. For additional model selection details, see Web Appendix 2.
For each exposure, we examined the fit of final selected models via plots of the residuals over time and plots of fitted model values versus observed values (48) . We also inspected the appropriateness of the negative binomial distribution by examining the relationship between the theoretical and actual residual variance for fitted values using the method developed by Ver Hoef and Boveng (49), as implemented by Imai et al. (37) .
We conducted multiple sensitivity analyses to examine the robustness of our findings (Web Appendix 3). All analyses were performed in RStudio, version 0.98.1103 (Boston, Massachusetts), with R, version 3.
(R Foundation for Statistical Computing) (50).
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RESULTS
An average of 24,058 children aged 8-35 months were under surveillance in the PopHR cohort each week (range, 21,396-27,061). The total number of AGE hospitalizations over the study period was 2,505, with the number of weekly hospitalizations ranging from 0 to 18.
At the effective start date of the rotavirus vaccine program, age-adjusted rotavirus ≥1-and ≥2-dose vaccine coverage among children aged 8-35 months was 6.9% (95% confidence interval (CI): 2.6, 17.0), and 6.6% (95% CI: 2.5, 16.8), respectively. Between the start date of our coverage estimates and the study end date, age-adjusted ≥1-dose vaccine coverage ranged from 3.9% to 87.0%, while ≥2-dose vaccine coverage ranged from 3.9% to 72.5%. Time series plots of weekly AGE hospitalization rates are presented in conjunction with the dichotomous and continuous representations of our exposure in Figure 1 .
Model selection
For both exposures, the final selected models included the following terms to adjust for seasonality, long-term trends, and infection dynamics: a linear term for week time, cubic B-spline transformation of calendar week time with 6 annual knots, separate annual and biennial sine terms for the periods before and after the program began, a linear term for annual rotavirus season, and separate linear terms for the "population recovered and immune" for the periods before and after the program began. For our binary exposure, we additionally included a product term to account for a weekly change in trend in the program period after the program began. To account for residual autocorrelation in the final models, we selected an autoregressive term of 1-week lagged model residuals, with little evidence of residual autocorrelation in the models adjusting for seasonality, long-term trends, and infection dynamics after its implementation. Candidate and final models are presented in Web Tables 1-7 . Analyses of nonlinearity between vaccine coverage and the log outcome in adjusted models demonstrated that a linear characterization of our exposure was appropriate (Web Appendix 1, Web Tables 8-11 , Web Figures 1-2) .
The fit of the model with ≥1-dose rotavirus coverage was similar to that with ≥2-dose coverage (AIC difference = 0.2). Models with either ≥1-or ≥2-dose coverage had similar to moderately better fit than the dichotomous exposure model (AIC differences = 2.6 and 2.8, respectively). Plots of the fitted counts from each exposure model versus observed counts of AGE hospitalizations are presented in Figure 2 . A negative binomial distribution was deemed appropriate to model all exposures.
Impact of the vaccination program
On average, weekly rates of AGE hospitalizations in the periods before and after the program began were 1.341 (95% CI: 1.238, 1.443) and 0.696 (95% CI: 0.606, 0.786) per 10,000 children, respectively, accounting for a relative decrease of 48.1% (95% CI: 37.6, 56.8) in crude weekly rates in the period after the program began. After adjustment, the Quebec vaccine program was associated with a 51.2% (95% CI: 28.5, 66.7) relative decline in weekly rates of AGE hospitalizations among children 8-35 months of age at study completion.
Prior to the uptake of any vaccine, the mean weekly rate of AGE hospitalizations was 1.369 (95% CI: 1.263, 1.474) per 10,000 children aged 8-35 months. We estimated that a 10% increase in ≥1-dose rotavirus coverage was associated with an 11.9% (95% CI: 8.8, 14.9) relative decrease in crude weekly rates of AGE hospitalizations, or a 7.1% (95% CI: 3.5, 10.5) relative decrease in adjusted rates. Where the continuous exposure was characterized as a 10% increase in ≥2-dose coverage, we estimated a crude relative weekly rate reduction of 13.8% (95% CI: 10.3, 17.3), or an adjusted relative decline of 8.3% (95% CI: 4.2, 12.3). When we generalized our adjusted estimates to the maximum coverage achieved during the study period, we estimated a relative decline in weekly AGE hospitalization rates of 47.2% (95% CI: 26.9, 61.9) for an increase in ≥1-dose coverage to 87.0%, or 46.8% (95% CI: 26.7, 61.3) for an increase in ≥2-dose coverage to 72.5%. Adjusted model coefficients, rate ratios, and 95% confidence intervals are presented in Table 1 . Results of sensitivity analyses were consistent with primary analyses (Web Figure 3) .
DISCUSSION
After adjustment for seasonality and other factors, we estimated that a 10% increase in ≥1-dose rotavirus vaccine coverage was associated with a 7% relative decrease in the weekly rate of AGE hospitalizations among children aged 8-35 months. For an increase to 87% rotavirus ≥1-dose coverage, or the highest coverage level observed during the study period, we estimated that adjusted weekly rates of AGE hospitalization declined by 47%. To our knowledge, only Bar-Zeev et al. (51) have also estimated the overall effect of a 10% increase in rotavirus vaccine coverage (in Malawi); unfortunately, their data are not directly comparable to ours due to differences between study outcomes, populations, and rotavirus disease dynamics.
In comparison with our nonstandard estimate, we found that weekly rates of AGE hospitalizations were lower in the period after the program began-by 51% at study completion, 3 years after the implementation of the Quebec vaccine program. While these analyses are valid to ascertain the overall effect of the whole program up to that point, and similar to results found for maximum coverage levels, they are not easily applied to future periods, particularly if there is a change in population vaccine coverage.
Direct comparison of the overall program effect with otherwise similar jurisdictions with differing vaccine coverage is also not straightforward, because interpretation of program-related reductions must be made in the context of population vaccine coverage. While most systematic reviews or meta-analyses that compare overall effects between vaccine programs report jurisdictional vaccine coverage in their narrative or a results table (52) (53) (54) (55) (56) , it is difficult for readers to synthesize this information. Other systematic reviews or meta-analyses account for differences in vaccine coverage by stratifying overall effect estimates by coverage (57, 58) ; while this is a better method for comparison, coverage strata in these systematic reviews or meta-analyses were overly broad (i.e., coverage <50% vs. ≥50%, or low/ moderate/high coverage), which might be insufficient to adjust for differences in program effects due to vaccine coverage.
While it is also possible to directly adjust for vaccine coverage in meta-analyses using statistical models (59), the overall effect estimates from primary studies might not reflect a period after a program's implementation that has uniform vaccine coverage. This might be particularly true for the evaluation of new vaccine programs, such as rotavirus, where program estimates represent a period during which population coverage is rapidly changing (60-64); thus, direct adjustment for vaccine coverage in pooled analyses might not be possible or accurate.
In each of these scenarios, estimates of the overall effect attributable to a per-unit change in vaccine coverage might be particularly useful to extrapolate estimates to other coverage levels, directly compare estimates between otherwise similar jurisdictions, or to incorporate into statistical models pooling program effect estimates from differing jurisdictions. For these reasons, we suggest that the overall effect attributable to a per-unit change in vaccine coverage might be a useful measure to supplement traditional methods to estimate the overall effect of a vaccine program, where vaccine coverage data are available.
Limitations
Our analyses have some limitations. First, we caution that our results are intended to estimate the overall effect of vaccination at the time of our evaluation, and thus, are generalizable only to settings with comparable rotavirus disease dynamics and to vaccine-coverage levels observed within the range examined in the present study. Further, although we found that a loglinear relationship was appropriate to model the effect of increasing vaccine coverage, this assumption should be examined by researchers in future analyses and might not be accurate for rotavirus vaccine-coverage levels beyond those observed in Abbreviations: CI, confidence interval; RR, rate ratio. a Model coefficients represent the log(RR) for each exposure derived from fully adjusting negative-binomial generalized linear models implemented with a log-link function. In separate models, the Quebec rotavirus vaccine program was characterized as either as a dichotomous variable with linear trend in the period after the program or as a continuous variable, representing the percentage of ≥1-or ≥2-dose rotavirus vaccine coverage in the population.
this study. Second, our approach ignores the potential implications of vaccination in other population subgroups on indirect effects; however, this is not an issue in the present study because our study population represents the entire population eligible for vaccination, and thus, all indirect effects included in our effect estimates necessarily arise from vaccination within the study population. Where analyses do not include the entire vaccineeligible population, we recommend that researchers account for vaccine coverage among subpopulations not included in the analyses. Third, we did not include sampling error for coverage estimates in our analyses and, given our method of ascertaining coverage, we might slightly underestimate coverage (25) ; nonetheless, we conducted multiple sensitivity analyses that explored the effect of differing coverage estimates, and we did not find meaningful differences in our results. Last, we were unable to ascertain the effect of the program on rotavirus hospitalizations directly; however, broadening our definition to AGE hospitalizations should only attenuate our effect estimates because only a portion of these represent rotavirus and, thus, would be vaccine-preventable.
Conclusion
In the evaluation of a vaccine program, researchers should consider estimating the overall effect attributable to a per-unit increase in vaccine coverage in the population, in addition to estimating the overall effect of the whole program. In our examination of the effect of the Quebec rotavirus vaccine program, we estimated that each 10% increase in ≥1-dose rotavirus vaccine coverage was associated with a 7% relative decrease in the rate of weekly AGE hospitalizations among children 8-35 months of age. Using this approach of estimating the incremental effect of increasing coverage should promote comparisons of overall effect estimates across settings with differing coverage.
